Regulus initiated with an Outperform at Oppenheimer

Oppenheimer analyst Andreas Argyrides initiated coverage of Regulus with an Outperform rating and $7 price target. The analyst says Regulus is set to advance its next-generation anti-miR17 oligonucleotide, RGLS8429, into a pivotal trial for the treatment of autosomal dominant polycystic kidney disease. RGLS8429 offers the prospect of disease modification and is positioned as the preferred treatment for high-risk ADPKD patients, the analyst tells investors in a research note. The firm sees a clear path toward accelerated approval that could lead to approval in the second half of 2028.